UCLA study: Promising target for CAR T-cell therapy leads to potent antitumor responses against cutaneous and rare melanomas

Advanced PET/CT imaging can improve long-term outcomes in recurrent prostate cancer, UCLA-led study finds

A five-year retrospective study led by investigators at the UCLA Health Jonsson Comprehensive Cancer Center shows that prostate-specific membrane antigen PET/CT scans can help doctors target treatment more precisely for men whose prostate cancer returns after surgery, improving long-term outcomes and potentially reducing unnecessary side effects.

February 13, 2026

Vol.52 No.06

Clinical Roundup

Neoadjuvant pembrolizumab helps shrink tumors in patients with desmoplastic melanoma

In a recent multi-institutional clinical trial, 71% of patients who received the immunotherapy drug pembrolizumab, an anti-PD-1 immune checkpoint inhibitor, before surgery had no detectable cancer remaining at the time of surgery.

February 06, 2026

Vol.52 No.05

Clinical Roundup

Researchers create blueprint for designing CD8 killer T cells to kill cancer cells

Researchers have uncovered new genetic rules that determine how CD8 killer T cells choose between becoming long-lasting, protective defenders or slipping into exhausted, dysfunctional states.

February 06, 2026

Vol.52 No.05

Clinical Roundup

Itismeran autogene + Keytruda demonstrated improvement in recurrence-free survival in neoadjuvant melanoma

Moderna and Merck announced median five-year follow-up data from the phase IIb KEYNOTE-942/mRNA-4157-P201 study, evaluating intismeran autogene (mRNA-4157 or V940), an investigational mRNA-based individualized neoantigen therapy, in combination with Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy, in patients with high-risk melanoma (stage 3/4) following complete resection.

January 30, 2026

Vol.52 No.04

Clinical Roundup

Lab-grown organoids reveal how glioblastoma resists treatment

UCLA scientists have developed advanced miniature 3D tumor organoid models that make it possible to study glioblastoma tumors in a setting that closely mirrors the human brain, shedding light on how the aggressive cancer interacts with surrounding brain cells and the immune system to become more invasive and resistant to therapy.

January 30, 2026

Vol.52 No.04

Clinical Roundup

UTSW researchers boost the power of CAR T cells to fight cancer

UT Southwestern Medical Center researchers have discovered that increasing the levels of a protein called BACH2 makes engineered cancer-fighting immune cells behave more like stem cells, improving their therapeutic effectiveness. The study suggests new strategies for improving the efficacy of these immune cells, known as chimeric antigen receptor T cells.

January 30, 2026

Vol.52 No.04

UCLA study: Promising target for CAR T-cell therapy leads to potent antitumor responses against cutaneous and rare melanomas

YOU MAY BE INTERESTED IN

Advanced PET/CT imaging can improve long-term outcomes in recurrent prostate cancer, UCLA-led study finds

Neoadjuvant pembrolizumab helps shrink tumors in patients with desmoplastic melanoma

Researchers create blueprint for designing CD8 killer T cells to kill cancer cells

Itismeran autogene + Keytruda demonstrated improvement in recurrence-free survival in neoadjuvant melanoma

Lab-grown organoids reveal how glioblastoma resists treatment

UTSW researchers boost the power of CAR T cells to fight cancer

Renew today!

Subscriber content

Never miss an issue!

Login